EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Fabry disease cardiomyopathy: A state-of-the-art review

Shivangi Pande, Fahimeh Varzideh, Jessica Gambardella, Stanislovas S Jankauskas, Federica Andrea Cerasuolo, Letizia Spinelli, Urna Kansakar, Antonio De Luca, Irwin J Kurland, Simone Sidoli, Guido Iaccarino, Junichi Sadoshima und 1 weitere

Progress in Cardiovascular Diseases · 2025

DOI: 10.1016/j.pcad.2025.08.003 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Progress in Cardiovascular Diseases, 2025. Verfasst von Shivangi Pande und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York City, NY 10461, USA. Hauptthemen laut MEDLINE: Fabry Disease, Cardiomyopathies. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 600 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIH Office of the Director.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabry disease or Anderson-Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of α-galactosidase A (GLA), leading to systemic accumulation of globotriaosyl-ceramide (Gb3). Initially described in 1898 as a dermatological condition, Fabry disease is now recognized as a progressive multisystem disorder with significant cardiac involvement. Cardiomyopathy in Fabry disease arises from Gb3 accumulation in cardiac tissue, resulting in fibrosis, left ventricular hypertrophy (LVH), diastolic dysfunction, and heart failure. The deacylated derivative, lysoGb3, serves as a biomarker of cardiac involvement. Diagnosis relies on enzyme assays, genetic testing, and advanced cardiac imaging modalities like echocardiography and cardiac MRI. Management strategies are centered around enzyme replacement therapy, and prognosis varies due to phenotypic heterogeneity and severity of disease progression. Psychological and social burdens further complicate patient care. However, underdiagnosis remains a concerning issue, particularly in individuals with unexplained cardiomyopathies. Early recognition through increased clinical awareness and genetic screening is crucial for timely intervention. Ongoing research is essential to develop new therapies targeting the genetic and metabolic roots of the disease. This systematic review comprehensively examines current evidence regarding the mechanisms, diagnosis, treatment, and prognosis of cardiomyopathy associated with Fabry disease, providing insights that may enhance clinical practice and guide future research initiatives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry DiseaseCardiomyopathiesHumansEnzyme Replacement TherapyPrognosisPhenotypealpha-GalactosidaseVentricular Function, LeftGenetic Predisposition to DiseaseGenetic TestingPredictive Value of Tests

Stichwörter der Autor:innen

Anderson-Fabry diseaseDiastolic DysfunctionLysosomesMitochondria

Substanzen

alpha-Galactosidase

Autor:innen und Institutionen

  • Department of Medicine, Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York City, NY 10461, USA.
  • Department of Medicine, Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York City, NY 10461, USA; International Translational Research and Medical Education (ITME) Conso…
  • International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, "Federico II" University, Naples 80100, Italy; Department of Advanced Biomedical Sciences, "Federico II" University,…
  • Department of Mental and Physical Health and Preventive Medicine, Division of Human Anatomy, University of Campania "Luigi Vanvitelli", Naples 80138, Italy.
  • Department of Biochemistry and Department of Genetics, Albert Einstein College of Medicine, New York City, NY 10461, USA.
  • Department of Clinical Medicine and Surgery, "Federico II" University, Naples 80131, Italy.

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIH Office of the Director
  • National Heart, Lung, and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Diabetes Research Center
  • American Federation for Aging Research
  • National Center for Advancing Translational Sciences

Zitieren

APA

Pande, S., Varzideh, F., Gambardella, J., Jankauskas, S. S., Cerasuolo, F. A., Spinelli, L., Kansakar, U., De Luca, A., Kurland, I. J., Sidoli, S., Iaccarino, G., Sadoshima, J., & Santulli, G. (2025). Fabry disease cardiomyopathy: A state-of-the-art review. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2025.08.003

Vancouver

Pande S, Varzideh F, Gambardella J, Jankauskas SS, Cerasuolo FA, Spinelli L, et al. Fabry disease cardiomyopathy: A state-of-the-art review. Progress in Cardiovascular Diseases. 2025. doi:10.1016/j.pcad.2025.08.003

BibTeX
@article{Pande2025,
  author = {Pande, Shivangi and Varzideh, Fahimeh and Gambardella, Jessica and Jankauskas, Stanislovas S and Cerasuolo, Federica Andrea and Spinelli, Letizia and Kansakar, Urna and De Luca, Antonio and Kurland, Irwin J and Sidoli, Simone and Iaccarino, Guido and Sadoshima, Junichi and Santulli, Gaetano},
  title = {Fabry disease cardiomyopathy: A state-of-the-art review},
  journal = {Progress in Cardiovascular Diseases},
  year = {2025},
  doi = {10.1016/j.pcad.2025.08.003}
}
Kostenlos starten →